DRG Executive Search Consultants
DRG'S CURRENT SEARCHES

Alzheimer’s Drug Discovery Foundation (Chief Executive Officer (Search closed))

Print Description          Email This To A Friend




More than 44 million people worldwide suffer from Alzheimer’s – with many more fearing the future onset of this debilitating disease. There remains to be no way to cure or effectively slow the progress of Alzheimer’s. But there is hope in drug discovery.

OPPORTUNITY

The Alzheimer’s Drug Discovery Foundation (“ADDF”) is currently seeking to fill the newly created position of Chief Executive Officer. The ADDF CEO will lead the strategic, financial and philanthropic growth of this high profile organization.

THE FOUNDATION

Founded in 2004 by Leonard and Ronald Lauder, the Alzheimer’s Drug Discovery Foundation (ADDF) is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer’s disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer’s and is considered a pioneer in the venture philanthropy model. Over time, the ADDF has awarded $80 million to fund more than 500 Alzheimer’s drug discovery programs and clinical trials in 18 countries. The ADDF devotes 100% of every dollar raised to Alzheimer’s drug discovery research.

Science is the backbone of the ADDF. In addition to the work in drug discovery, the Foundation develops innovative scientific programs and conferences to bring together experts to address critical challenges in new drug development. Dr. Howard Fillit, the Chief Science Officer, is a renowned leader in neuroscience and geriatric medicine and is supported by a team of four Ph.D. neuroscientists as well as an esteemed scientific review board comprised of experts from academia and industry.

ADDF Drug Development

The ADDF supports diverse, international research to develop new drugs for Alzheimer's and related dementias, including vascular, Lewy body, and frontotemporal dementias. The goal is to fill the critical translational funding gap that exists between basic research and later-stage drug development, while also producing more “shots on goal”. The ADDF funds three categories of research:

     *Drug discovery and preclinical development (critical seed funding for early-stage drug research that may go unfunded)

     *Clinical trials, including an increasing number of biotechnology ventures

     *Early detection, such as biomarkers and neuroimaging

The Venture Philanthropy Model

ADDF is a pioneer in biomedical venture philanthropy. The Foundation funds scientists in both academia and the biopharmaceutical industry – these commitments encompass potential investment returns, either as a percentage of future royalties or as an investment in the company itself. All returns on investment recycle into more research. More than $14 million has been invested in biotechnology programs to date, of which $2.8 million has been reinvested into new drug research. ADDF grantees have leveraged more than $2 billion in follow-on commitments from government, pharmaceutical and venture capital sources.

The Alzheimer’s Drug Discovery Fund raised more than $22 million in 2015 for research grants. For more information on the Alzheimer’s Drug Discovery Foundation please visit www.alzdiscovery.org.